Business Context and Reporting Period
Company: Bionano Genomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 19, 2018
Reporting Period: Events occurring on November 19, 2018.
Status: Emerging Growth Company.
Key Financial Metrics and Agreements
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). It reports specific financial obligations and equity issuances:
- Success Fee Reduction: The success fee payable to Western Alliance Bank regarding the August 2018 IPO was reduced from $210,000 to $160,000.
- Warrant Exercise Price Adjustment: The exercise price for existing Bank Warrants was reduced from $20.56 per share to $6.99 per share.
- Service Provider Warrants Issued:
- LifeSci Capital, LLC: Warrant for 44,183 shares at $8.25/share (satisfying $150,000 obligation).
- Russell Creative Group: Warrant for 3,311 shares at $8.25/share (satisfying $15,000 obligation).
Material Changes Versus Prior Period
The filing details amendments to existing agreements rather than operational performance changes:
- Debt/Cost Reduction: A $50,000 reduction in the immediate cash obligation (Success Fee) to Western Alliance Bank.
- Equity Dilution Terms: Significant reduction in the strike price of Bank Warrants, increasing their potential value to the holder.
- Liability Settlement: Conversion of $165,000 in accrued service fees into equity warrants rather than cash payments.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or strategic commentary beyond the execution of the amendment and warrant issuances.
Risks and Contingencies:
- Dilution Risk: Issuance of new warrants and reduction of exercise prices on existing warrants may dilute existing shareholders.
- Unregistered Sales: The new warrants were issued under Section 4(a)(2) of the Securities Act of 1933, exempt from registration.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the new 47,494 warrants on potential dilution.
- Confirm the remaining terms of the Loan and Security Agreement with Western Alliance Bank to understand future cash flow obligations.
- Review the full text of the Amendment Agreement (Exhibit 10.1) for any covenants or conditions not summarized in the 8-K.
- Check subsequent filings for the actual cash payment of the reduced $160,000 success fee.